ライフサイエンスコーパス: lymphangiogenesis

1 es new lymphatic vessel growth (inflammatory lymphangiogenesis).

2 clusively by sprouting from embryonic veins (lymphangiogenesis).

3 by promoting tissue fibrosis and inhibiting lymphangiogenesis.

4 rogression, concomitant with increased tumor lymphangiogenesis.

5 and VEGF-C production and exhibited aberrant lymphangiogenesis.

6 and metastasis by blocking angiogenesis and lymphangiogenesis.

7 esis, implicating arteries as drivers of gut lymphangiogenesis.

8 CoA for epigenetic modifications critical to lymphangiogenesis.

9 ury are observed in IBD along with increased lymphangiogenesis.

10 uring involution coincides with inflammatory lymphangiogenesis.

11 C) is a secreted growth factor essential for lymphangiogenesis.

12 lockade completely ablates TNF-alpha-induced lymphangiogenesis.

13 cer metastasis and correlated with decreased lymphangiogenesis.

14 ing by IC might induce VEGF-A and lymph node lymphangiogenesis.

15 ay, which is critical in embryonic and adult lymphangiogenesis.

16 markedly and significantly influenced tumor lymphangiogenesis.

17 at fibroblast growth factor 2 (FGF2) induces lymphangiogenesis.

18 factor for driving both tumor and lymph node lymphangiogenesis.

19 inoic acid (RA) concentration, in regulating lymphangiogenesis.

20 kers has advanced our understanding of tumor lymphangiogenesis.

21 ic cells, and lymphocytes are known to drive lymphangiogenesis.

22 L1R1 receptor activation by IL-1beta induced lymphangiogenesis.

23 th factor C (VEGF-C), is a major mediator of lymphangiogenesis.

24 (Adm) gene dosage within tumor cells affects lymphangiogenesis.

25 oncurrent suppression of hemangiogenesis and lymphangiogenesis.

26 provide a new avenue for inhibition of tumor lymphangiogenesis.

27 rn mice, we examined their potential role in lymphangiogenesis.

28 to sites of inflammation can also coordinate lymphangiogenesis.

29 amycin in promoting lung repair and reducing lymphangiogenesis.

30 F-C(+) cells, and reductions in inflammatory lymphangiogenesis.

31 ial receptor that mediates the FGF-2-induced lymphangiogenesis.

32 ation is a prerequisite for FGF-2-stimulated lymphangiogenesis.

33 that tumor-secreted growth factors stimulate lymphangiogenesis.

34 ng antibody markedly inhibited FGF-2-induced lymphangiogenesis.

35 alpha (HIF-1alpha) is a central regulator of lymphangiogenesis.

36 formation in both FGF-2- and VEGF-C-induced lymphangiogenesis.

37 t were measured in response to modulators of lymphangiogenesis.

38 alue in diseases accompanied by pathological lymphangiogenesis.

39 , paricalcitol showed markedly reduced renal lymphangiogenesis.

40 rsely, an excess of VEGF-C induced meningeal lymphangiogenesis.

41 mors prevents pulmonary metastasis and tumor lymphangiogenesis.

42 rare lymphatic vessels suggestive of limited lymphangiogenesis.

43 nd galectin-8 inhibitors reduce inflammatory lymphangiogenesis.

44 iated with increased lymphatic clearance and lymphangiogenesis.

45 cal role of macrophages in the regulation of lymphangiogenesis.

46 g protein, galectin-8, promotes pathological lymphangiogenesis.

47 MI induced robust, intramyocardial capillary lymphangiogenesis, adverse remodeling of epicardial prec

48 strate for the first time that physiological lymphangiogenesis also occurs in primarily avascular sit

49 of VEGF-C activity with VEGFR-3-Ig inhibited lymphangiogenesis and angiogenesis and reduced infiltrat

50 ntial therapeutic tool for the modulation of lymphangiogenesis and angiogenesis in a variety of disea

51 gs and lymph nodes by inhibiting TCM-induced lymphangiogenesis and angiogenesis in the pre-metastatic

52 of CCBE1 into mouse skeletal muscle enhanced lymphangiogenesis and angiogenesis induced by adeno-asso

53 een measured in colorectal tumors undergoing lymphangiogenesis and correlated with metastasis.

54 herefore to analyze the effects of TGFBIp on lymphangiogenesis and determine whether TGFBIp-related l

55 actor VEGF-D promotes metastasis by inducing lymphangiogenesis and dilatation of the lymphatic vascul

56 hermore, local treatment with IL-10 promoted lymphangiogenesis and faster egress of macrophages from

57 a, while overexpression of sVEGFR-3 inhibits lymphangiogenesis and hemangiogenesis in a murine suture

58 duced by VEGF-C. sVEGFR-3 knockdown leads to lymphangiogenesis and hemangiogenesis in the mouse corne

59 This observation suggests a novel program of lymphangiogenesis and identifies a property of lymphatic

60 tion resulted in VEGF-A-dependent intranodal lymphangiogenesis and increased DC number.

61 y FOXC1 and FOXC2 as essential regulators of lymphangiogenesis and indicate a new potential mechanist

62 provide the first evidence that LPA promotes lymphangiogenesis and induces IL-8 production in LECs; w

63 of Adm in tumors induced sentinel lymph node lymphangiogenesis and led to an increased incidence of K

64 vidence that SEMA3F re-expression diminishes lymphangiogenesis and lymph node metastasis.

65 Whether lymphangiogenesis and lymph node-mediated immunity are i

66 ew mechanisms and therapeutic strategies for lymphangiogenesis and lymphangiogenesis-related diseases

67 Here, we determined that enhancing lymphangiogenesis and lymphatic function reduces experim

68 Lymphangiogenesis and lymphatic metastasis in mice beari

69 various lymphangiogenic factors in promoting lymphangiogenesis and lymphatic metastasis remains poorl

70 port that TNF-alpha markedly promotes tumour lymphangiogenesis and lymphatic metastasis.

71 s in Tnfr1(-/-) mice largely restores tumour lymphangiogenesis and lymphatic metastasis.

72 mor types, mainly through the stimulation of lymphangiogenesis and lymphatic metastasis.

73 TAMs) virtually eliminates TNF-alpha-induced lymphangiogenesis and lymphatic metastasis.

74 with lymph node positivity, was involved in lymphangiogenesis and lymphatic metastasis.

75 is SECs express Prox1, a master regulator of lymphangiogenesis and lymphatic phenotypes.

76 vide evidence to support the hypothesis that lymphangiogenesis and lymphatic transport are compensato

77 ent molecular pathways regulate inflammatory lymphangiogenesis and lymphatic vessel memory.

78 Lymphangiogenesis and lymphatic vessel remodeling are co

79 -C and sVEGFR3 significantly decreased graft lymphangiogenesis and lymphoid Th1 cell frequencies as c

80 -derived LECs enhanced wound healing through lymphangiogenesis and lymphvasculogenesis.

81 VEGFC signaling via VEGFR3 promotes lymphangiogenesis and metastasis by orthotopic colorecta

82 8 induction is a key step in mediating tumor lymphangiogenesis and metastasis, and they identify SOX1

83 s upregulated in breast cancer, resulting in lymphangiogenesis and metastasis.

84 W620 cancer cells dramatically reduced tumor lymphangiogenesis and metastasis.

85 along with other lymphatic diseases, such as lymphangiogenesis and obstructed lymphatic vessels.

86 kin imaging technique to visualize sprouting lymphangiogenesis and patterning at the lymphatic networ

87 al process that might contribute to aberrant lymphangiogenesis and persistent inflammation in the ski

88 demonstrate that 9-cisRA potently activates lymphangiogenesis and promotes lymphatic regeneration in

89 Herein, we show that IL-10 modulates corneal lymphangiogenesis and resolution of inflammation.

90 aptive immune response, followed by enhanced lymphangiogenesis and the development of OAD.

91 Insight into the regulatory mechanisms of lymphangiogenesis and the manner in which uncontrolled i

92 ted a strong correlation between peritumoral lymphangiogenesis and tumor dissemination.

93 we demonstrate the multifaceted dynamics of lymphangiogenesis and valvulogenesis associated with tra

94 thus provides an optimal tool to study both lymphangiogenesis and valvulogenesis upon a pathological

95 observed in patients with SLE; we found that lymphangiogenesis and VEGF-A were increased in the lymph

96 TGFbetaR-I inhibitor suppressed the enhanced lymphangiogenesis and VEGF-C expression associated with

97 tron 13 junction increases sKDR (suppressing lymphangiogenesis) and decreases mbKDR (inhibiting heman

98 vascular development and adult angiogenesis, lymphangiogenesis, and arteriogenesis.

99 lammation, fibroadipose deposition, impaired lymphangiogenesis, and dysfunctional lymphatic pumping.

100 thelial-cell-specific receptor important for lymphangiogenesis, and Ets-1 activates the promoter of V

101 organs show marked neoangiogenesis, aberrant lymphangiogenesis, and extensive induction of high endot

102 In HR PK, VEGFR1_MO decreased angiogenesis, lymphangiogenesis, and increased graft survival compared

103 o inflammation, lymphatic vessel remodeling, lymphangiogenesis, and lipid and small molecule transpor

104 ammatory circuits that promote angiogenesis, lymphangiogenesis, and metastasis, both at local sites a

105 s and other BMDCs that promote angiogenesis, lymphangiogenesis, and metastasis.

106 ted tumor growth, angiogenesis, intratumoral lymphangiogenesis, and metastasis.

107 F-C and VEGFR-3 as critical regulators of SC lymphangiogenesis, and provide a basis for further studi

108 orpholino-inhibited corneal angiogenesis and lymphangiogenesis, and suppressed graft rejection after

109 ranuloma access to secondary lymph organs by lymphangiogenesis, and that this process facilitates the

110 hat SOX18 is also critical for tumor-induced lymphangiogenesis, and we show that suppressing SOX18 fu

111 mplex virus keratitis, corneal pathology and lymphangiogenesis are ameliorated in Lgals8(-/-) mice.

112 Angiogenesis and lymphangiogenesis are crucial for cancer progression, pa

113 Controlled angiogenesis and lymphangiogenesis are essential for tissue development,

114 Current in vivo models to assess lymphangiogenesis are largely unphysiologic.

115 Inflammation and lymphangiogenesis are two cohesively coupled processes t

116 Presently, effects of VitD on lymphangiogenesis are unknown.

117 downregulation in CXCL14-expressing CAF and lymphangiogenesis as a novel component of CXCL14-promote

118 activators and small molecule inhibitors of lymphangiogenesis, as well as transplanted human endothe

119 Lymphangiogenesis associated with tertiary lymphoid stru

120 These results suggest that lymphangiogenesis associates with fibrosis through the T

121 on for 2 weeks before mating blocked ovarian lymphangiogenesis at all stages of follicle maturation,

122 distal pre-metastatic niches uncoupled from lymphangiogenesis at primary lesions.

123 eporter allowed us to tracking tumor-induced lymphangiogenesis at the tumor periphery and in lymph no

124 olecular level or how this process regulates lymphangiogenesis, because these complex molecular inter

125 R2(-/-) mice had the usual IL-1beta-mediated lymphangiogenesis but no neutrophil recruitment, suggest

126 gulates ischemia-mediated arteriogenesis and lymphangiogenesis, but its role in tumor angiogenesis is

127 macrophages, and conspicuous and persistent lymphangiogenesis, but surprisingly no angiogenesis.

128 ial cells; they show that sVEGFR-3 modulates lymphangiogenesis by impounding vascular endothelial gro

129 Inhibition of aGVHD-associated lymphangiogenesis by monoclonal antibodies against vascu

130 that HIF-1alpha is a critical coordinator of lymphangiogenesis by regulating the expression of lympha

131 dimerize, it is principally an antagonist of lymphangiogenesis by sequestering VEGF-C.

132 ion where we also monitor down-regulation of lymphangiogenesis by the glucocorticoid dexamethasone.

133 stitial fluid homeostasis, and dysfunctional lymphangiogenesis contributes to various pathological pr

134 Therefore, it is unclear whether (and how) lymphangiogenesis contributes to visceral metastasis.

135 cular remodeling and cytotrophoblast-induced lymphangiogenesis, contributing to bleeding, hypoxia, an

136 EGF-D expression, deepening understanding of lymphangiogenesis control during tumor formation.

137 role in cancer metastasis and inhibition of lymphangiogenesis could be valuable in fighting cancer d

138 In addition to lymphangiogenesis, COX-2 inhibition reduces many of the

139 istical difference in terms of angiogenesis, lymphangiogenesis, deposition of extracellular matrix, c

140 se data suggest that the function of Pdpn in lymphangiogenesis does not depend on threonine 34 in the

141 ogenesis inhibits liver metastasis, yet anti-lymphangiogenesis does not impact liver metastasis despi

142 e and likely synergize with VEGFA in corneal lymphangiogenesis during acute HSV-1 infection.

143 factor C (VEGF-C), its receptor VEGFR-3, and lymphangiogenesis during development of experimental obl

144 tor (CLR) are implicated in angiogenesis and lymphangiogenesis during embryogenesis and wound healing

145 The observed lymphangiogenesis during infection was reduced by inhibi

146 el function for neutrophils as organizers of lymphangiogenesis during inflammation.

147 hat characterize post-natal angiogenesis and lymphangiogenesis elicited by cutaneous wounds and infla

148 etion in mouse embryos results in failure of lymphangiogenesis, fluid accumulation in tissues, and le

149 response to cutaneous wounding, but enhances lymphangiogenesis following both dermal wounding and inf

150 ning the phased response of angiogenesis and lymphangiogenesis following injury.

151 ound healing and tissue repair, pathological lymphangiogenesis has been implicated in a number of chr

152 ic tissue transplantation, the inhibition of lymphangiogenesis has been successfully used to attenuat

153 une responses, and inflammation, the role of lymphangiogenesis has not been investigated during allog

154 age and suggest that treatments to stimulate lymphangiogenesis have promise for improving graft outco

155 dence indicates that inflammation-associated lymphangiogenesis (IAL) is not merely an endpoint event,

156 alginate microparticles, accelerated cardiac lymphangiogenesis in a dose-dependent manner and limited

157 val, corneal neovascularization, and corneal lymphangiogenesis in a group treated with both nanoparti

158 mediating tumor-induced hemangiogenesis and lymphangiogenesis in a murine model of breast cancer met

159 So far, a physiological role for lymphangiogenesis in a primarily avascular site such as

160 hether IL-1beta can promote angiogenesis and lymphangiogenesis in airways.

161 odoplanin(+) vessels, suggesting the lack of lymphangiogenesis in AMD and uveitis.

162 eover, 9-cisRA was found to activate in vivo lymphangiogenesis in animals in mouse trachea, Matrigel

163 , mesenteric lymph node lymphadenopathy, and lymphangiogenesis in both the mesentery and mucosa.

164 intimate interplay between inflammation and lymphangiogenesis in cancer metastasis, and propose ther

165 d glycoproteins that induce angiogenesis and lymphangiogenesis in cancer, thereby promoting tumor gro

166 We therefore sought to address the role of lymphangiogenesis in CLAD.

167 veloping protein-based therapeutics to drive lymphangiogenesis in clinical settings, such as lymphede

168 To investigate lymphangiogenesis in CNV, we generated CNV in animals by

169 l and highlighting the clinical relevance of lymphangiogenesis in corneal fluid homeostasis.

170 blood and lymphatic vessels, but the role of lymphangiogenesis in CRC progression has not been determ

171 rowth factor C (VEGF-C) is a major driver of lymphangiogenesis in embryos and adults.

172 s and pregnancy, as well as the necessity of lymphangiogenesis in follicle maturation and health, are

173 however, the molecular mechanisms underlying lymphangiogenesis in HNSCC is still poorly understood.

174 Reduced lymphangiogenesis in IL-10(-/-) and lysozyme M Cre Stat3

175 helial growth factor-C and decreased corneal lymphangiogenesis in IL-10-deficient mice (IL-10(-/-)).

176 We conclude that aGVHD is associated with lymphangiogenesis in intestinal lesions and in lymph nod

177 asive imaging method to visualize lymph node lymphangiogenesis in mice using radiolabeled antibodies

178 actor receptor 3 (VEGFR-3) antibody to block lymphangiogenesis in mice.

179 rsus-host disease (aGVHD) is associated with lymphangiogenesis in murine allo-HSCT models as well as

180 a transcription factor that is necessary for lymphangiogenesis in ontogeny and the maintenance of LVs

181 Molecular regulation of TLO LVs differs from lymphangiogenesis in ontogeny with a dependence on cytok

182 portant tool for studying the involvement of lymphangiogenesis in pathological processes.

183 contribute to UFF, but little is known about lymphangiogenesis in patients with UFF and peritonitis.

184 Moreover, the peptide inhibits lymphangiogenesis in primary tumors.

185 7 enhanced LEC in vitro activity and induced lymphangiogenesis in the cornea of wild-type (WT) mice.

186 ry gland conditioned medium, suggesting that lymphangiogenesis in the mammary gland is likely driven

187 iption factor SOX18 as a critical switch for lymphangiogenesis in the mouse embryo.

188 and metastasis by blocking angiogenesis and lymphangiogenesis in the pre-metastatic organs as well a

189 ength and volume of both hemangiogenesis and lymphangiogenesis in the suture-induced corneal angiogen

190 rs, collaboratively promote angiogenesis and lymphangiogenesis in the tumor microenvironment, leading

191 CIS growth, motility and invasion as well as lymphangiogenesis in the tumor microenvironment.

192 istration of neutralizing Ab to IL-6 blocked lymphangiogenesis in TNF-alpha(-/-) mice.

193 ontaining protein 1 (CCBE1) is essential for lymphangiogenesis in vertebrates and has been associated

194 as active as wild-type Pdpn-Fc in inhibiting lymphangiogenesis in vitro and also inhibited lymphangio

195 A inhibition, we discovered that LPA-induced lymphangiogenesis in vitro and IL-8 production are media

196 9-cis RA promotes lymphangiogenesis in vitro and in vivo and has promise a

197 rm of the protein, Pdpn-Fc, leads to reduced lymphangiogenesis in vitro and in vivo.

198 ase (MEK) 1/2 inhibitors substantially block lymphangiogenesis in vitro and in vivo.

199 Macrophage-dependent lymphangiogenesis in vitro was triggered upon inflammaso

200 etin 2 (Ang2) stimulated hemangiogenesis and lymphangiogenesis in vitro, whereas SK1-I inhibited each

201 e levels significantly increased peritumoral lymphangiogenesis in vivo and promoted the trans-differe

202 promotes LEC collapse and potently inhibits lymphangiogenesis in vivo.

203 ymphangiogenesis in vitro and also inhibited lymphangiogenesis in vivo.

204 ic effects in vitro and is able to attenuate lymphangiogenesis in vivo.

205 monitoring of physiological and pathological lymphangiogenesis in vivo.

206 udy uncovers a unique molecular mechanism of lymphangiogenesis in which galectin-8-dependent crosstal

207 We propose a dual origin of gut lymphangiogenesis in which prior arterial growth is requ

208 Moreover, our understanding of lymphangiogenesis (in melanomas and other tumour types)

209 VEGF-C to induce lymphatic vessel expansion (lymphangiogenesis) in primary tumors and in draining sen

210 (HSV-1) induces new lymphatic vessel growth (lymphangiogenesis) in the cornea via expression of vascu

211 s been linked primarily to the regulation of lymphangiogenesis, in the present study, we demonstrate

212 increased the knowledge of the mechanisms of lymphangiogenesis, including the roles of transcription

213 Following TSC2(-/-) ASM cell administration, lymphangiogenesis increased in lungs as indicated by mor

214 development during embryogenesis as well as lymphangiogenesis induced by specific growth factors, du

215 valves and can be used to study pathological lymphangiogenesis induced by various insults.

216 ng signaling through VEGFR-3 and suppressing lymphangiogenesis induced by VEGF-C. sVEGFR-3 knockdown

217 In the absence of B cells, intranodal lymphangiogenesis induced during prolonged inflammation

218 in vitro effectiveness of norcantharidin, a lymphangiogenesis inhibitor, as a potential co-adjuvant

219 d highly regulated model of angiogenesis and lymphangiogenesis involving vascular endothelial growth

220 Lymphangiogenesis is a highly regulated process involved

221 Lymphangiogenesis is a key component of various inflamma

222 signaling and suggest that VEGFR-2-dependent lymphangiogenesis is a mechanism that restricts tissue i

223 In oncology the inhibition of lymphangiogenesis is an established therapeutic concept

224 Lymphangiogenesis is an important physiological response

225 logeneic transplantation, galectin-8-induced lymphangiogenesis is associated with an increased rate o

226 Excessive lymphangiogenesis is associated with cancer progression

227 Tumor lymphangiogenesis is associated with increased immune su

228 immunization or contact hypersensitization, lymphangiogenesis is decreased and local inflammation is

229 Lymphangiogenesis is essential for fluid homeostasis in

230 genesis and determine whether TGFBIp-related lymphangiogenesis is important for the metastasis of tum

231 Lymphangiogenesis is induced via vascular endothelial gr

232 nic organ failure in kidney transplantation, lymphangiogenesis is not altered in CLAD patients.

233 mammary gland, suggesting that mammary gland lymphangiogenesis is not likely regulated directly by th

234 rucial for cancer progression, particularly, lymphangiogenesis is pivotal for metastasis in breast ca

235 However, the role of TGFBIp signaling in lymphangiogenesis is poorly understood.

236 Pdpn(-/-) mice; likewise, galectin-8-induced lymphangiogenesis is reduced in Pdpn(-/-) mice.

237 Together, these studies reveal that lymphangiogenesis is regulated by two distinct proteolyt

238 Mechanistically, VEGF-C-induced lymphangiogenesis is significantly reduced in the Lgals8

239 Lymphangiogenesis is supported by 2 homologous VEGFR3 li

240 cytokine, in the regulation of inflammatory lymphangiogenesis is undetermined.

241 Lymphangiogenesis is upregulated during incidents of tra

242 thelial growth factor-C remarkably increased lymphangiogenesis, lymphatic function, and lymphatic end

243 ession promoted peritumoral and intratumoral lymphangiogenesis, lymphatic invasion, and distant metas

244 lution window decreased normal mammary gland lymphangiogenesis, mammary tumor-associated lymphangioge

245 Moreover, our data reveal that therapeutic lymphangiogenesis may be a promising new approach for th

246 ally avascular cornea, however, pathological lymphangiogenesis mediates diseases like corneal transpl

247 We studied the role of the lymphangiogenesis mediator vascular endothelial growth f

248 Attenuation of lymphangiogenesis might represent a novel strategy to ta

249 conditions will allow for broad screening of lymphangiogenesis modulators, as well as help define cel

250 Lymphatic vessel growth or lymphangiogenesis occurs during embryonic development an

251 We conclude that robust lymphangiogenesis occurs in mouse lungs after M. pulmoni

252 ta indicate that physiologic COX-2-dependent lymphangiogenesis occurs in the postpartum mammary gland

253 blockage or down-regulation leads to reduced lymphangiogenesis or altered vessel branching.

254 rative state that is distinct from embryonic lymphangiogenesis or quiescent lymphatic vessels observe

255 tions in both physiological and pathological lymphangiogenesis, particularly in tumor metastasis, mak

256 Lymphangiogenesis plays a pivotal role in diverse pathol

257 Together, our findings provide evidence that lymphangiogenesis plays an unexpectedly beneficial role

258 ivation of ERbeta inhibited angiogenesis and lymphangiogenesis, possibly mediated by impaired vascula

259 selective therapeutic stimulation of cardiac lymphangiogenesis post-MI.

260 e demonstrate that neutrophils contribute to lymphangiogenesis primarily by modulating vascular endot

261 lymphatic vessels develop luminal valves as lymphangiogenesis proceeds.

262 gene, which participates in angiogenesis and lymphangiogenesis, produces two functionally distinct pr

263 terized, it is not clear how or if increased lymphangiogenesis promotes disease.

264 apeutic strategies for lymphangiogenesis and lymphangiogenesis-related diseases at various stages and

265 effect on decreasing neovascularization and lymphangiogenesis, resulting in increased graft survival

266 VEGFR1_MO decreased angiogenesis and lymphangiogenesis, resulting in increased graft survival

267 e VEGFR-3 (VEGF-C/D Trap) completely blocked lymphangiogenesis, showing its dependence on VEGFR-3 lig

268 bility via VEGF receptor 2 (VEGFR2), whereas lymphangiogenesis signals are transduced by VEGFC/D via

269 factor (VEGF)-C/VEGF receptor-3 signaling in lymphangiogenesis, significant new insights were obtaine

270 Moreover, CCBE1 was required for in vivo lymphangiogenesis stimulated by VEGFC but not VEGFD.

271 factor midkine is a systemic inducer of neo-lymphangiogenesis that defines patient prognosis.

272 Despite roles in pathological neo-lymphangiogenesis, the characterization of an endogenous

273 Lymphangiogenesis, the growth of lymphatic vessels, is e

274 F)-D is capable of inducing angiogenesis and lymphangiogenesis through signaling via VEGF receptor (V

275 VEGFR-3-mediated lymphangiogenesis thus appears to modulate the folliculo

276 of residual inflammation-induced lymph node lymphangiogenesis, thus, might hamper the identification

277 We conclude that lymphangiogenesis triggered by IL-1beta overexpression i

278 lymphangiogenesis, mammary tumor-associated lymphangiogenesis, tumor cell invasion into lymphatics,

279 promotes tumor cell invasion on collagen and lymphangiogenesis via activation of beta1-integrin recep

280 10 indirectly regulates inflammatory corneal lymphangiogenesis via macrophages.

281 Pharmacological blockade of lymphangiogenesis via VEGFR-3 inhibition results in incr

282 Reduced lymphangiogenesis was also observed in the nonrelated me

283 Sprouting lymphangiogenesis was evident at 7 days.

284 The effect of IL-10 on lymphangiogenesis was indirect via macrophages, because

285 Peritumoral lymphangiogenesis was present in the ciliary body in uve

286 In rodents, mammary lymphangiogenesis was upregulated during weaning-induced

287 ddition, FGF2 but not VEGF-C-induced in vivo lymphangiogenesis, was also inhibited.

288 s of lymphatic regeneration and inflammatory lymphangiogenesis, we explored the hypothesis that hypox

289 transplantation, graft hemeangiogenesis and lymphangiogenesis were evaluated by immunohistochemistry

290 Neutrophil aggregation and suppressed lymphangiogenesis were evident in the soft tissue at 21

291 l stage of vascular remodeling and sprouting lymphangiogenesis were examined by comparing the effects

292 n ANG2-blocking antibody inhibited embryonic lymphangiogenesis, whereas endothelium-specific ANG2 ove

293 VEGF-C signaling through VEGFR-3 promotes lymphangiogenesis, which is a clinically relevant target

294 nflammation through VEGF-A-driven lymph node lymphangiogenesis, which is controlled by FcgammaRIIb.

295 Accumulation of Tregs and lymph node lymphangiogenesis, which may influence the fate of metas

296 dpnT34A-Fc might be an improved inhibitor of lymphangiogenesis with fewer toxic side effects.

297 of VitD and the deleterious associations of lymphangiogenesis with renal disease, we here tested the

298 We found that stimulation of lymphangiogenesis with VEGF-C156S, a mutant form of VEGF

299 esized that other factors may be involved in lymphangiogenesis, with proinflammatory cytokines as the

300 antibody (Ab) blocked HSV-1-mediated corneal lymphangiogenesis within the first 5 days postinfection.